Identification
- Summary
Adenine is a purine base which forms a component of DNA among other functions and is present in many multivitamins.
- Brand Names
- As 3, Cpda-1 Blood Collection System, Leukotrap, Rejuvesol, Sag-M
- Generic Name
- Adenine
- DrugBank Accession Number
- DB00173
- Background
A purine base and a fundamental unit of adenine nucleotides.
- Type
- Small Molecule
- Groups
- Approved, Nutraceutical
- Structure
Structure for Adenine (DB00173)
- Weight
- Average: 135.1267
Monoisotopic: 135.054495185 - Chemical Formula
- C5H5N5
- Synonyms
- 6-Aminopurine
- Adenin
- Adenine
- Vitamin B4
Pharmacology
- Indication
For nutritional supplementation, also for treating dietary shortage or imbalance
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Adenine (sometimes known as vitamin B4) combines with the sugar ribose to form adenosine, which in turn can be bonded with from one to three phosphoric acid units, yielding AMP, ADP and ATP . These adenine derivatives perform important functions in cellular metabolism. Adenine is one of four nitrogenous bases utilized in the synthesis of nucleic acids. A modified form of adenosine monophosphate (cyclic AMP) is an imporant secondary messenger in the propagation of many hormonal stimuli. Adenine is an integral part of the structure of many coenzymes. Adenosine (adenine with a ribose group) causes transient heart block in the AV node of the heart. In individuals suspected of suffering from a supraventricular tachycardia (SVT), adenosine is used to help identify the rhythm. Certain SVTs can be successfully terminated with adenosine.
- Mechanism of action
Adenine forms adenosine, a nucleoside, when attached to ribose, and deoxyadenosine when attached to deoxyribose, and it forms adenosine triphosphate (ATP), which drives many cellular metabolic processes by transferring chemical energy between reactions.
Target Actions Organism UAdenine phosphoribosyltransferase Not Available Humans UDNA Not Available Humans US-methyl-5'-thioadenosine phosphorylase Not Available Humans UNicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase Not Available Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) UAcetyl-CoA carboxylase 2 Not Available Humans ULow molecular weight phosphotyrosine protein phosphatase Not Available Humans U5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase Not Available Escherichia coli (strain K12) UPeroxisomal trans-2-enoyl-CoA reductase Not Available Humans UA/G-specific adenine glycosylase Not Available Escherichia coli (strain K12) UNucleoside deoxyribosyltransferase-I Not Available Lactobacillus helveticus USRSF protein kinase 2 Not Available Humans UHolliday junction ATP-dependent DNA helicase RuvB Not Available Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Adenylosuccinate Lyase Deficiency Disease Xanthine Dehydrogenase Deficiency (Xanthinuria) Disease Xanthinuria Type I Disease Mitochondrial DNA Depletion Syndrome Disease Myoadenylate Deaminase Deficiency Disease Purine Metabolism Metabolic Purine Nucleoside Phosphorylase Deficiency Disease Lesch-Nyhan Syndrome (LNS) Disease Gout or Kelley-Seegmiller Syndrome Disease Mercaptopurine Action Pathway Drug action Adenine Phosphoribosyltransferase Deficiency (APRT) Disease Adenosine Deaminase Deficiency Disease AICA-Ribosiduria Disease Molybdenum Cofactor Deficiency Disease Azathioprine Action Pathway Drug action Thioguanine Action Pathway Drug action Xanthinuria Type II Disease - Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The metabolism of Abacavir can be decreased when combined with Adenine. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Adenine. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Adenine. Axitinib The metabolism of Axitinib can be decreased when combined with Adenine. Bazedoxifene The metabolism of Bazedoxifene can be decreased when combined with Adenine. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Adenine hydrochloride 364H11M7OD 2922-28-3 UQVDQSWZQXDUJB-UHFFFAOYSA-N Adenine sulfate 741GJF3K9M 321-30-2 LQXHSCOPYJCOMD-UHFFFAOYSA-N - International/Other Brands
- Leuco-4
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Additive Formula 3 Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US 
Additive Formula 3 Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US Additive Formula 3 Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US Additive Formula 3 Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US Additive Formula 3 Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 6-aminopurines. These are purines that carry an amino group at position 6. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Imidazopyrimidines
- Sub Class
- Purines and purine derivatives
- Direct Parent
- 6-aminopurines
- Alternative Parents
- Aminopyrimidines and derivatives / Imidolactams / Imidazoles / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- 6-aminopurine / Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Azole / Heteroaromatic compound / Hydrocarbon derivative / Imidazole / Imidolactam
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- 6-aminopurines, purine nucleobase (CHEBI:16708) / purines (C00147) / a ring (ADENINE-RING)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- JAC85A2161
- CAS number
- 73-24-5
- InChI Key
- GFFGJBXGBJISGV-UHFFFAOYSA-N
- InChI
- InChI=1S/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10)
- IUPAC Name
- 7H-purin-6-amine
- SMILES
- NC1=C2NC=NC2=NC=N1
References
- Synthesis Reference
Eiichi Yonemitsu, Tomiya Isshiki, Yasuhiko Kijima, "Process for preparing adenine." U.S. Patent US4059582, issued March, 1964.
US4059582- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000034
- KEGG Drug
- D00034
- KEGG Compound
- C00147
- PubChem Compound
- 190
- PubChem Substance
- 46507319
- ChemSpider
- 185
- BindingDB
- 50228485
- 290
- ChEBI
- 16708
- ChEMBL
- CHEMBL226345
- ZINC
- ZINC000000000882
- Therapeutic Targets Database
- DAP000982
- PharmGKB
- PA448048
- PDBe Ligand
- ADE
- Wikipedia
- Adenine
- PDB Entries
- 1aha / 1bjq / 1cb0 / 1d2a / 1giu / 1hqc / 1ifs / 1j1r / 1jh8 / 1jys … show 147 more
- MSDS
- Download (72.5 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Other Sickle Cell Disease (SCD) 1 4 Withdrawn Basic Science Heart Defects,Congenital 1 1 Completed Basic Science Human Immunodeficiency Virus (HIV) Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Kit; solution Intravenous Injection, solution Intravenous Liquid Intravenous Kit Intravenous Solution Intravenous Solution Extracorporeal Solution Unknown - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 360 dec °C PhysProp water solubility 1030 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -0.09 HANSCH,C ET AL. (1995) logS -2.12 ADME Research, USCD pKa 4.15 (at 25 °C) KORTUM,G ET AL (1961) - Predicted Properties
Property Value Source Water Solubility 11.5 mg/mL ALOGPS logP -0.38 ALOGPS logP -0.57 Chemaxon logS -1.1 ALOGPS pKa (Strongest Acidic) 10.29 Chemaxon pKa (Strongest Basic) 3.66 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 80.48 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 38.22 m3·mol-1 Chemaxon Polarizability 12.29 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9733 Blood Brain Barrier + 0.9395 Caco-2 permeable - 0.5225 P-glycoprotein substrate Non-substrate 0.6835 P-glycoprotein inhibitor I Non-inhibitor 0.98 P-glycoprotein inhibitor II Non-inhibitor 0.9805 Renal organic cation transporter Non-inhibitor 0.8573 CYP450 2C9 substrate Non-substrate 0.9144 CYP450 2D6 substrate Non-substrate 0.8966 CYP450 3A4 substrate Non-substrate 0.7957 CYP450 1A2 substrate Non-inhibitor 0.6459 CYP450 2C9 inhibitor Non-inhibitor 0.9567 CYP450 2D6 inhibitor Non-inhibitor 0.988 CYP450 2C19 inhibitor Non-inhibitor 0.9441 CYP450 3A4 inhibitor Non-inhibitor 0.9246 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9024 Ames test AMES toxic 0.6746 Carcinogenicity Non-carcinogens 0.9197 Biodegradation Not ready biodegradable 0.9857 Rat acute toxicity 2.4381 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9646 hERG inhibition (predictor II) Non-inhibitor 0.906
Spectra
- Mass Spec (NIST)
- Download (7.29 KB)
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 121.5328701 predictedDarkChem Lite v0.1.0 [M-H]- 127.9056411 predictedDarkChem Lite v0.1.0 [M-H]- 121.5886701 predictedDarkChem Lite v0.1.0 [M-H]- 121.7055701 predictedDarkChem Lite v0.1.0 [M-H]- 116.98201 predictedDeepCCS 1.0 (2019) [M+H]+ 122.7103701 predictedDarkChem Lite v0.1.0 [M+H]+ 132.5161035 predictedDarkChem Lite v0.1.0 [M+H]+ 122.8185701 predictedDarkChem Lite v0.1.0 [M+H]+ 122.6742701 predictedDarkChem Lite v0.1.0 [M+H]+ 120.82607 predictedDeepCCS 1.0 (2019) [M+Na]+ 122.1051701 predictedDarkChem Lite v0.1.0 [M+Na]+ 143.6821433 predictedDarkChem Lite v0.1.0 [M+Na]+ 122.2404701 predictedDarkChem Lite v0.1.0 [M+Na]+ 122.0610701 predictedDarkChem Lite v0.1.0 [M+Na]+ 129.6119 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Amp binding
- Specific Function
- Catalyzes a salvage reaction resulting in the formation of AMP, that is energically less costly than de novo synthesis.
- Gene Name
- APRT
- Uniprot ID
- P07741
- Uniprot Name
- Adenine phosphoribosyltransferase
- Molecular Weight
- 19607.535 Da
References
- Barrett C, Alley J, Pulido JC, Spurling H, Li P, Parsons T, Mallender WD, Bembenek ME: Configuration of a scintillation proximity assay for the activity assessment of recombinant human adenine phosphoribosyltransferase. Assay Drug Dev Technol. 2006 Dec;4(6):661-9. [Article]
- Di Pietro V, Perruzza I, Amorini AM, Balducci A, Ceccarelli L, Lazzarino G, Barsotti P, Giardina B, Tavazzi B: Clinical, biochemical and molecular diagnosis of a compound homozygote for the 254 bp deletion-8 bp insertion of the APRT gene suffering from severe renal failure. Clin Biochem. 2007 Jan;40(1-2):73-80. Epub 2006 Oct 19. [Article]
- Katahira R, Ashihara H: Profiles of purine biosynthesis, salvage and degradation in disks of potato (Solanum tuberosum L.) tubers. Planta. 2006 Dec;225(1):115-26. Epub 2006 Jul 15. [Article]
- Katahira R, Ashihara H: Role of adenosine salvage in wound-induced adenylate biosynthesis in potato tuber slices. Plant Physiol Biochem. 2006 Oct;44(10):551-5. Epub 2006 Oct 9. [Article]
- Boitz JM, Ullman B: Leishmania donovani singly deficient in HGPRT, APRT or XPRT are viable in vitro and within mammalian macrophages. Mol Biochem Parasitol. 2006 Jul;148(1):24-30. Epub 2006 Mar 15. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Unknown
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Simon R, Heithoff DM, Mahan MJ, Samuel CE: Comparison of tissue-selective proinflammatory gene induction in mice infected with wild-type, DNA adenine methylase-deficient, and flagellin-deficient Salmonella enterica. Infect Immun. 2007 Dec;75(12):5627-39. Epub 2007 Sep 24. [Article]
- Ichida H, Maeda K, Ichise H, Matsuyama T, Abe T, Yoneyama K, Koba T: In silico restriction landmark genome scanning analysis of Xanthomonas oryzae pathovar oryzae MAFF 311018. Biochem Biophys Res Commun. 2007 Nov 23;363(3):852-6. Epub 2007 Sep 24. [Article]
- Mamdouh W, Dong M, Kelly RE, Kantorovich LN, Besenbacher F: Coexistence of homochiral and heterochiral adenine domains at the liquid/solid interface. J Phys Chem B. 2007 Oct 25;111(42):12048-52. Epub 2007 Oct 5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- S-methyl-5-thioadenosine phosphorylase activity
- Specific Function
- Catalyzes the reversible phosphorylation of S-methyl-5'-thioadenosine (MTA) to adenine and 5-methylthioribose-1-phosphate. Involved in the breakdown of MTA, a major by-product of polyamine biosynth...
- Gene Name
- MTAP
- Uniprot ID
- Q13126
- Uniprot Name
- S-methyl-5'-thioadenosine phosphorylase
- Molecular Weight
- 31235.76 Da
References
- Chow WA, Bedell V, Gaytan P, Borden E, Goldblum J, Hicks D, Slovak ML: Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas. Cancer Genet Cytogenet. 2006 Apr 15;166(2):95-100. [Article]
- Chattopadhyay S, Zhao R, Tsai E, Schramm VL, Goldman ID: The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Mol Cancer Ther. 2006 Oct;5(10):2549-55. [Article]
- Singh V, Schramm VL: Transition-state structure of human 5'-methylthioadenosine phosphorylase. J Am Chem Soc. 2006 Nov 15;128(45):14691-6. [Article]
- Kind
- Protein
- Organism
- Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)
- Pharmacological action
- Unknown
- General Function
- Nicotinate-nucleotide-dimethylbenzimidazole phosphoribosyltransferase activity
- Specific Function
- Catalyzes the synthesis of alpha-ribazole-5'-phosphate from nicotinate mononucleotide (NAMN) and 5,6-dimethylbenzimidazole (DMB).
- Gene Name
- cobT
- Uniprot ID
- Q05603
- Uniprot Name
- Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase
- Molecular Weight
- 36612.305 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Maggio-Hall LA, Escalante-Semerena JC: Alpha-5,6-dimethylbenzimidazole adenine dinucleotide (alpha-DAD), a putative new intermediate of coenzyme B12 biosynthesis in Salmonella typhimurium. Microbiology. 2003 Apr;149(Pt 4):983-90. [Article]
- Cheong CG, Escalante-Semerena JC, Rayment I: Structural investigation of the biosynthesis of alternative lower ligands for cobamides by nicotinate mononucleotide: 5,6-dimethylbenzimidazole phosphoribosyltransferase from Salmonella enterica. J Biol Chem. 2001 Oct 5;276(40):37612-20. Epub 2001 Jul 5. [Article]
- Trzebiatowski JR, Escalante-Semerena JC: Purification and characterization of CobT, the nicotinate-mononucleotide:5,6-dimethylbenzimidazole phosphoribosyltransferase enzyme from Salmonella typhimurium LT2. J Biol Chem. 1997 Jul 11;272(28):17662-7. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Metal ion binding
- Specific Function
- Catalyzes the ATP-dependent carboxylation of acetyl-CoA to malonyl-CoA. Carries out three functions: biotin carboxyl carrier protein, biotin carboxylase and carboxyltransferase. Involved in inhibit...
- Gene Name
- ACACB
- Uniprot ID
- O00763
- Uniprot Name
- Acetyl-CoA carboxylase 2
- Molecular Weight
- 276538.575 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Rasmussen JT, Rosendal J, Knudsen J: Interaction of acyl-CoA binding protein (ACBP) on processes for which acyl-CoA is a substrate, product or inhibitor. Biochem J. 1993 Jun 15;292 ( Pt 3):907-13. [Article]
- Witters LA, Mendel DB, Colliton JW: Modulation of acetyl-CoA carboxylase by inhibitors of IMP dehydrogenase: implications for insulin regulation. Arch Biochem Biophys. 1987 Jan;252(1):130-5. [Article]
- Itani SI, Saha AK, Kurowski TG, Coffin HR, Tornheim K, Ruderman NB: Glucose autoregulates its uptake in skeletal muscle: involvement of AMP-activated protein kinase. Diabetes. 2003 Jul;52(7):1635-40. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Non-membrane spanning protein tyrosine phosphatase activity
- Specific Function
- Acts on tyrosine phosphorylated proteins, low-MW aryl phosphates and natural and synthetic acyl phosphates. Isoform 3 does not possess phosphatase activity.
- Gene Name
- ACP1
- Uniprot ID
- P24666
- Uniprot Name
- Low molecular weight phosphotyrosine protein phosphatase
- Molecular Weight
- 18042.315 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Wang S, Stauffacher CV, Van Etten RL: Structural and mechanistic basis for the activation of a low-molecular weight protein tyrosine phosphatase by adenine. Biochemistry. 2000 Feb 15;39(6):1234-42. [Article]
- Magherini F, Gamberi T, Paoli P, Marchetta M, Biagini M, Raugei G, Camici G, Ramponi G, Modesti A: The in vivo tyrosine phosphorylation level of yeast immunophilin Fpr3 is influenced by the LMW-PTP Ltp1. Biochem Biophys Res Commun. 2004 Aug 20;321(2):424-31. [Article]
- Ostanin K, Pokalsky C, Wang S, Van Etten RL: Cloning and characterization of a Saccharomyces cerevisiae gene encoding the low molecular weight protein-tyrosine phosphatase. J Biol Chem. 1995 Aug 4;270(31):18491-9. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- General Function
- Methylthioadenosine nucleosidase activity
- Specific Function
- Catalyzes the irreversible cleavage of the glycosidic bond in both 5'-methylthioadenosine (MTA) and S-adenosylhomocysteine (SAH/AdoHcy) to adenine and the corresponding thioribose, 5'-methylthiorib...
- Gene Name
- mtnN
- Uniprot ID
- P0AF12
- Uniprot Name
- 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase
- Molecular Weight
- 24353.725 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Singh V, Lee JE, Nunez S, Howell PL, Schramm VL: Transition state structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli and its similarity to transition state analogues. Biochemistry. 2005 Sep 6;44(35):11647-59. [Article]
- Walker RD, Duerre JA: S-adenosylhomocysteine metabolism in various species. Can J Biochem. 1975 Mar;53(3):312-9. [Article]
- Singh V, Schramm VL: Transition-state analysis of S. pneumoniae 5'-methylthioadenosine nucleosidase. J Am Chem Soc. 2007 Mar 14;129(10):2783-95. Epub 2007 Feb 14. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- PECR
- Uniprot ID
- Q9BY49
- Uniprot Name
- Peroxisomal trans-2-enoyl-CoA reductase
- Molecular Weight
- 32544.11 Da
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- General Function
- Metal ion binding
- Specific Function
- Adenine glycosylase active on G-A mispairs. MutY also corrects error-prone DNA synthesis past GO lesions which are due to the oxidatively damaged form of guanine: 7,8-dihydro-8-oxoguanine (8-oxo-dG...
- Gene Name
- mutY
- Uniprot ID
- P17802
- Uniprot Name
- Adenine DNA glycosylase
- Molecular Weight
- 39148.835 Da
- Kind
- Protein
- Organism
- Lactobacillus helveticus
- Pharmacological action
- Unknown
- General Function
- Nucleoside deoxyribosyltransferase activity
- Specific Function
- Not Available
- Gene Name
- ptd
- Uniprot ID
- Q8RLY5
- Uniprot Name
- Nucleoside 2-deoxyribosyltransferase
- Molecular Weight
- 18713.08 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein serine/threonine kinase activity
- Specific Function
- Serine/arginine-rich protein-specific kinase which specifically phosphorylates its substrates at serine residues located in regions rich in arginine/serine dipeptides, known as RS domains and is in...
- Gene Name
- SRPK2
- Uniprot ID
- P78362
- Uniprot Name
- SRSF protein kinase 2
- Molecular Weight
- 77525.955 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
- Pharmacological action
- Unknown
- General Function
- Four-way junction helicase activity
- Specific Function
- The RuvA-RuvB complex in the presence of ATP renatures cruciform structure in supercoiled DNA with palindromic sequence, indicating that it may promote strand exchange reactions in homologous recom...
- Gene Name
- ruvB
- Uniprot ID
- Q5SL87
- Uniprot Name
- Holliday junction ATP-dependent DNA helicase RuvB
- Molecular Weight
- 35973.305 Da
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
- Gene Name
- UGT1A1
- Uniprot ID
- P22309
- Uniprot Name
- UDP-glucuronosyltransferase 1-1
- Molecular Weight
- 59590.91 Da
References
- Nishimura Y, Maeda S, Ikushiro S, Mackenzie PI, Ishii Y, Yamada H: Inhibitory effects of adenine nucleotides and related substances on UDP-glucuronosyltransferase: structure-effect relationships and evidence for an allosteric mechanism. Biochim Biophys Acta. 2007 Nov;1770(11):1557-66. Epub 2007 Aug 8. [Article]
Drug created at June 13, 2005 13:24 / Updated at January 02, 2024 23:42